| Adults | Pregnant/breastfeeding | Children | |
Intranasal antihistamines |
Azelastine 0.14 mg/spray, one spray per nostril, twice daily (Azep Levocabastine 0.5 mg/mL, two sprays per nostril, twice daily (Livostin |
Azelastine – B3 Levocabastine – B3 |
From age five years: Azelastine 0.14 mg/spray, one spray per nostril, twice daily (Azep |
Oral antihistamines |
Loratadine 10 mg once daily (Loraclear Hayfever Relief Fexofenadine 120–180 mg once daily (Telfast Cetirizine 5–20 mg once daily (Zetop |
Loratadine – B1 Cetirizine – B2 Fexofenadine – B2 |
From age two years: From age two years: |
Intranasal corticosteroids |
Fluticasone 50–100 mcg/nostril once daily (Flixonase, Nasaclear Triamcinolone 55 mcg/nostril twice daily (Telnase Beclomethasone 50–100 mcg/nostril twice daily (Alanase Budesonide 50–100 mcg/nostril once daily (Butacort Aqueous |
Budesonide – A Beclomethasone – B3 Fluticasone – B3 |
From age 12 years: Fluticasone 50 mcg/nostril once daily (Flixonase, Nasaclear From age six years: Budesonide 50 mcg/nostril once daily (Butacort Aqueous |
Intranasal decongestants |
Xylometazoline 0.1%, one spray/nostril two to four times per day, maximum five days (Otrivin spray or drops Oxymetazoline 0.5 mg/mL (Drixine |
Xylometazoline Not recommended unless benefit outweighs risk (Category C) |
Xylometazoline 0.05%, one spray/nostril two to three times per day, max five days (Otrivin Junior spray or drops |
Oral corticosteroid |
Prednisone 20–40 mg once daily for five to seven days |
Prednisone – A |
Prednisone 10 mg once daily for five to seven days |
Intranasal anticholinergic |
Ipratropium bromide 0.03% two sprays, two to three times daily (Apo-Ipravent |
Ipratropium bromide – B1 |
From age 12 years: Ipratropium bromide 0.03% two sprays, two to three times daily (Apo-Ipravent |
Intranasal sodium cromoglycate |
Sodium cromoglycate Nasal Spray 4%, one spray/nostril two to four times per day |
Sodium cromoglycate – A |
From age six years: Sodium cromoglycate Nasal Spray 4%, one spray/nostril two to four times per day |
Ocular antihistamines |
Levocabastine, one drop per eye, three times per day (Livostin eye drops Lodoxamide, one drop per eye, four times per day (Lomide Olopatadine, one drop per eye, two times per day (Patanol Ketotifen, one drop per eye, two times per day (Zaditen Naphazoline + pheniramine (Visine, Naphcon-A Antazoline + naphazoline (Albalon-A N.B. naphazoline can cause rebound hypaeremia (redness) if used for longer than ten days |
Lodoxamide – B1 Olopatadine – B1 Ketotifen – B1 Levocabastine – B3 |
From age six years: Levocabastine, one drop per eye, three times per day (Livostin eye drops From age four years: Lodoxamide, one drop per eye, four times per day (Lomide From age three years: Olopatadine, one drop per eye, two times per day (Patanol From age three years: Ketotifen, one drop per eye, two times per day (Zaditen |
Australian Drug Evaluation Committee classification of drugs in pregnancy (summarised)11
| Category A | No evidence of harmful effects to the human foetus. |
| Category B1 | No evidence of harmful effects to the human foetus observed, but limited number of human studies. Animal studies have shown no increased risk of foetal harm. |
| Category B2 | No evidence of harmful effects to the human foetus observed, but limited number of human or animal studies. |
| Category B3 | No evidence of harmful effects to the human foetus observed, but limited number of human studies. Animal studies have shown evidence of increased risk of foetal harm, the significance of which is uncertain in humans. |
| Category C | May cause, or may be suspected of causing, harmful effects on the human foetus or neonate without causing malformations. Drug should only be used if benefit outweighs risk |
= Fully subsidised,
= Partly subsidised,
= Not subsidised